Guangzhou Baiyunshan Pharmaceutical Holdings Company LimitedSSE: 600332

"Corporate Value and Return Enhancement" Action Plan 2026

Jun 23, 2026 · Issued by Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited via Shanghai Stock Exchange

Filed with SSE · Jun 23, 2026

On 6ix: 6ix.com/news/corporate-value-and-return-enhancement-action-plan-2026-16

"Corporate Value and Return Enhancement" Action Plan 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited on 6ix

Earlier from Guangzhou Baiyunshan Pharmaceutical

Announcement on Branch Receiving Drug Registration CertificateJun 11
Announcement on Implementation of Dividend Distribution for 2025Jun 10
Announcement on Completing Term Change of the Board of Directors and Appointing Senior Management MembersMay 30
Announcement on Election of Employee Representative DirectorMay 16
Announcement on Convening Performance Briefing for 2025 and Q1 2026May 15

Later from Guangzhou Baiyunshan Pharmaceutical

Announcement on Completion of Legal Representative Change Registration and Renewal of Business LicenseJul 1
Announcement on Subsidiary's Drug Passing Generic Drug Consistency EvaluationJul 10
Indicative Announcement on the Pre-Listing of the Capital Increase and Share Expansion of a SubsidiaryJul 11
Announcement on the Receipt of a Macao Drug Registration Certificate by a BranchJul 21
Announcement on Change of "Drug Manufacturing License" of SubsidiaryAug 5

All Guangzhou Baiyunshan Pharmaceutical news releases

Follow Guangzhou Baiyunshan Pharmaceutical into a list and get an email when it puts out news.

Follow Guangzhou Baiyunshan Pharmaceutical